VHL and renal cell adenocarcinoma: This therapy is targeted towards adult patients with VHL-associated RCC, as well as those suffering from central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, and has been approved by the Food and Drug Administration (FDA) [29,66].